沙美特罗替卡松粉吸入剂联合孟鲁司特对支气管哮喘患儿细胞免疫及血清瘦素、嗜酸性粒细胞趋化因子、ECP、LPO的影响

目的探讨沙美特罗替卡松粉吸人剂联合孟鲁司特对支气管哮喘患儿细胞免疫及血清瘦素、嗜酸性粒细胞趋化因子、嗜酸性粒细胞阳离子蛋白（ECP）和脂质过氧化物（LPO）的影响。方法将榆林市儿童医院2011年10月-2012年12月收治的90例支气管哮喘患儿根据治疗方法分为研究组和对照组，每组各45例，研究组给予沙美特罗替卡松粉吸入剂联合盂鲁司特治疗，对照组给予沙美特罗替卡松粉吸入剂治疗。比较两组患儿治疗前后细胞免疫及血清瘦素、嗜酸性粒细胞趋化因子、ECP、LPO的变化情况。结果治疗前两组患儿的CD3＋、CD4＋、CD8’及CD4／CD8水平，差异无统计学意义（均P〉0．05）。治疗6：12周时研究组患儿的CD3＋、CD4＋、CD4／CD8f（64．35±7．55）％，（36．42±4．22）％，（1．69±0．15）；（68．56±8．11）％，（39．01±4．77）％，（1．85±0．17）]明显高于对照组（60．02±6．04）％，（32．96±3．23）％，（1．25±0．14）；（63．31±6．87）％，（34．82±3．88）％，（1．42±0．16）]，差异有统计学意义（均P〈0．05）；而研究组CD8±（28．66±2．45）％]明显低于对照组（25．21±5．43）％]，差异有统计学意义（P〈0．05）。治疗前两组患儿的血清瘦素、嗜酸性粒细胞趋化因子、ECP、LPO比较，差异无统计学意义（均P〉0．05）。治疗6、12周后研究组患儿的血清瘦素、嗜酸性粒细胞趋化因子、ECP、LPO水平（7．05±0．48）μg／L，（16．35±1．94）ng／L，（11．03±1．35）pg／L，（9．46±0．10）nmol／L；（6．52±0．47）μg／L，（6．48±O．90）ng／L，（6．05±0．79）pg/L，（7．03：t0．55）nmol／L]均低于对照组（8．73±0．72）μg／L，（25．24±3．15）ng／L，（16．25±1．76）pg/L，（12．83±1．50）nmol／L；（7．95±0．55）μg/L，（9．25±1．03）ng／L，（10．09±1．24）pg／L，（10．22±1．09）nmol／L]，差异有统计学意义（P〈0．05）。结论沙美特罗替卡松粉吸人剂联合孟鲁司特对支气管哮喘患儿细胞免疫及血清瘦素、嗜酸性粒细胞趋化因子、ECP、LPO水平的改善有重要作用。

The impact of Salmeterol Assigned Powder Inhalant joint Montelukast on cellular immunity in children with bronchial asthma and serum leptin,eotaxin, ECP,LPO

Objective To explore the impact of Salmeterol Assigned Powder Inhalant joint Montelukast on cellular immunity in children with bronchial asthma and serum leptin, eotaxin, ECP, LPO. Methods 90 cases of children with bronchial asthma were selected from Children＇s Hospital of Yulin City from October 2011 to December 2012, they were divided into research group and the control group according to the treatment, 45 cases in each group, the research group was given Salmeterol Assigned Powder Inhalant joint Montelukast, the control group was given Salmeterol Assigned Powder Inhalant. The changes of immune cells and serum leptin, eotaxin, ECP, LPO in children before and after treatment were compared. Results The levels of CD3＋, CD4＋, CD8＋ and CD4/CD8 in two groups of children before treatment had no statistically significant differences （P 〉 0.05）. The levels of CD3＋, CD4＋ and CD4/CD8 of children in research group （64.35±7.55）%, （36.42±4.22）%, （1.69± 0.15）; （68.56±8.11）%, （39.01±4.77）%, （1.85±0.17）] were significantly higher than the control group （60.02±6.04）%, （32.96± 3.23）%, （1.25±0.14）; （63.31±6.87）%, （34.82±3.88）%, （1.42±0.16）], the differences were statistically significant （P 〈 0.05）; but the level of CD8± of children in research group （28.66±2.45）%] was significantly lower than the control group （25.21 ± 5.43）%], the difference was statistically significant （P 〈 0.05）. The children＇s serum leptin, eotaxin, ECP, LPO in two groups of children before treatment had no statistically significant difference （P 〉 0.05）. The serum leptin, eotaxin, ECP and LPO level in the research group （7.05±0.48） μg/L, （16.35±1.94） ng/L, （11.03±1.35） pg/L, （9.46±0.10） nmol/L; （6.52±0.47） μg/L,（6.48±0.90） ng/L, （6.05±0.79） pg/L, （7.03±0.55） nmol/L] after treatment for 6, 12 weeks were lower than the control group （8.73±0.72） μg/L, （25.24±3.15） ng/L, （16.25±1.76） pg/L, （12.83±1.50） nmol/L; （7.95±0.55） μg/L, （9.25±1.03） ng/L, （10.09± 1.24） pg/L, （10.22±1.09） nmol/L], the differences were statistically significant （P 〈 0.05）. Conclusion Salmeterol Assigned Powder Inhalant joint Montelukast on cellular immunity in children with bronchial asthma and serum leptin, eotaxin, improve- ment of ECP and LPO level play an important role.